Spark Ther­a­peu­tics shares slide af­ter a set­back on its he­mo­phil­ia gene ther­a­py study

Shares of Spark Ther­a­peu­tics $ONCE, the most ad­vanced gene ther­a­py com­pa­ny in a grow­ing field, were bad­ly dent­ed this morn­ing af­ter the Pfiz­er $PFE part­ner not­ed that one of 7 pa­tients treat­ed with their he­mo­phil­ia B treat­ment ex­pe­ri­enced an im­mune re­sponse to the vi­ral de­liv­ery ve­hi­cle they use.

That’s ex­act­ly what you don’t want to see in a gene ther­a­py study, es­pe­cial­ly one this small, and Spark’s shares dropped 17% in a nasty re­ac­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.